alzhub.org
Get help now — free helplines

You can call any of these for free. You do not need a diagnosis, an appointment, or a crisis to call — questions and plain exhaustion are reasons enough.

  • Alzheimer's Association 24/7 Helpline 800-272-3900 24 hours a day, 365 days a year Free, confidential support and information for people with dementia, caregivers, families and the public. Master's-level clinicians. Also Spanish.
  • 988 Suicide & Crisis Lifeline 988 24/7 Call or text 988, or chat at 988lifeline.org. For anyone in emotional distress or a mental-health crisis, including caregivers.
  • Alzheimer's Foundation of America (AFA) Helpline 866-232-8484 9:00 am - 9:00 pm ET, seven days a week Licensed social workers providing support, info and referrals. Also text message and web chat. Text: 646-586-5283

In a medical emergency, call 911. More numbers, and what each line does, on the help page.

Home › Research › Topics › real-world-implementation

real-world-implementation

2 studies tagged real-world-implementation, dated 2026-07-01. Bibliography: BibTeX (.bib) · RIS (.ris)

Newest in this topic

  1. Real-world implementation of lecanemab in Alzheimer's disease: A Japanese cohort 2026-07-01
  2. Real-world implementation of lecanemab in Korean patients at a tertiary memory clinic: Safety, ARIA risk, and early treatment patterns 2026-07-01

Studies

2 studies carry this tag.

Date range

2026

Top journals

  • Alzheimer's & dementia (Amsterdam, Netherlands) 2

Newest first, then by address. Each study has a usefulness score out of 100 (rubric version 4.0); tap a score to see what makes it up. Tags were assigned automatically from each study's title and summary. The same studies as a filter in the library.

  1. Real-world implementation of lecanemab in Alzheimer's disease: A Japanese cohort

    ✓ Peer-reviewed alzhub usefulness score 62 out of 100. Alzheimer's & dementia (Amsterdam, Netherlands) 2026-07-01 Treatments

    Lecanemab was feasible and generally well tolerated under structured MRI monitoring in routine Japanese practice.

  2. Real-world implementation of lecanemab in Korean patients at a tertiary memory clinic: Safety, ARIA risk, and early treatment patterns

    ✓ Peer-reviewed alzhub usefulness score 78 out of 100. Alzheimer's & dementia (Amsterdam, Netherlands) 2026-07-01 Treatments

    In this prospective Korean cohort, lecanemab was generally well tolerated.

All topic tags with their study counts